Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alterity Therapeutics ( (AU:ATH) ) has shared an update.
Alterity Therapeutics has announced a change in the director’s interest notice, specifically regarding Brian Meltzer’s holdings. The notice reveals that there was a disposal of 7,000,000 unlisted options expiring on September 17, 2025, at $0.09, with no consideration involved. This change in holdings may impact the company’s stock dynamics and reflects ongoing adjustments in its governance and financial strategies.
More about Alterity Therapeutics
Alterity Therapeutics Limited operates in the biotechnology industry, focusing on developing therapeutic products for neurodegenerative diseases. The company is known for its innovative approaches to treating conditions such as Alzheimer’s and Parkinson’s diseases, aiming to address unmet medical needs in these areas.
YTD Price Performance: 20.0%
Average Trading Volume: 13,820,661
Technical Sentiment Signal: Sell
Current Market Cap: A$130.5M
For a thorough assessment of ATH stock, go to TipRanks’ Stock Analysis page.